CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,502 enrolled
Drug / intervention
Lansoprazoledrug
Likely dose
Lansoprazole 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02099708
NCT02099708N/ACompleted
CompareCT.gov

Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs

Takeda·observational·Posted Mar 31, 2014·Updated Oct 27, 2016

In Brief

An observational study evaluating Lansoprazole for Gastric or Duodenal Ulcers. Completed, enrolled 3,502 participants.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) therapy for up to 12 months in the routine clinical setting in patients receiving oral non-steroidal anti-inflammatory drugs (NSAIDs)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric or Duodenal Ulcers
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2014
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.3 years ago

Interventions

Lansoprazoledrug

Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg